Dechra will acquire Gallant Pet, Inc., a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell therapies for pets. This complementary transaction is aligned with Dechra’s long-term strategy to serve unmet needs in specialty care. Dechra shares our commitment to innovation and addressing unmet needs in veterinary medicine. I couldn't … [Read more...]
